These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 39306)

  • 21. [Dopaminergic receptor activity and the evolution of schizophrenia].
    Fodoreanu L
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1985; 30(2):131-4. PubMed ID: 2864729
    [No Abstract]   [Full Text] [Related]  

  • 22. Dopamine and schizophrenia.
    Crow TJ; Johnstone EC; Longden A; Owen F
    Adv Biochem Psychopharmacol; 1978; 19():301-9. PubMed ID: 29450
    [No Abstract]   [Full Text] [Related]  

  • 23. Dissociable properties of dopamine neurons im the nigrostriatal and mesolimbic dopamine systems.
    Koob GF; Del Fiacco M; Iversen SD
    Adv Biochem Psychopharmacol; 1977; 16():589-95. PubMed ID: 560793
    [No Abstract]   [Full Text] [Related]  

  • 24. Schizophrenia and tardive dyskinesia: is schizophrenia also a "denervation hypersensitivity"?
    Kapit RM
    Med Hypotheses; 1977; 3(5):207-10. PubMed ID: 904502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of chronic ethanol consumption on the mesolimbic and nigrostriatal dopamine systems.
    Pellegrino SM; Druse MJ
    Alcohol Clin Exp Res; 1992 Apr; 16(2):275-80. PubMed ID: 1534209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Roles of dopamine and its receptors in generation of choreic movements.
    Kanazawa I; Murata M; Kimura M
    Adv Neurol; 1993; 60():107-12. PubMed ID: 8093572
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Variability of response to neuroleptics in schizophrenia: clinical, pharmacologic, and neuroendocrine correlates.
    Gelder M; Kolakowska T
    Compr Psychiatry; 1979; 20(5):397-408. PubMed ID: 39704
    [No Abstract]   [Full Text] [Related]  

  • 28. Psychopharmacological implications of dopamine and dopamine antagonists: a critical evaluation of current evidence.
    Hornykiewicz O
    Annu Rev Pharmacol Toxicol; 1977; 17():545-59. PubMed ID: 17361
    [No Abstract]   [Full Text] [Related]  

  • 29. Cocaine, Neuroleptics, and tardive dyskinesia as paleocortical escape.
    Howard JS
    Integr Physiol Behav Sci; 1996; 31(4):306-14. PubMed ID: 8982762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Down-regulation of central dopamine receptors in schizophrenia.
    Zemlan FP; Hitzemann RJ; Hirschowitz J; Garver DL
    Am J Psychiatry; 1985 Nov; 142(11):1334-7. PubMed ID: 2865903
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The striatonigral fibres and the feedback control of dopamine metabolism.
    Tulloch IF; Arbuthnott GW; Wright AK; Garcia-Munoz M; Nicolaou NM
    Psychol Med; 1978 Aug; 8(3):471-82. PubMed ID: 30106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dopamine and the action of opiates: a reevaluation of the dopamine hypothesis of schizophrenia. With special consideration of the role of endogenous opioids in the pathogenesis of schizophrenia.
    Schmauss C; Emrich HM
    Biol Psychiatry; 1985 Nov; 20(11):1211-31. PubMed ID: 2996642
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground.
    Weinberger DR; Lipska BK
    Schizophr Res; 1995 Aug; 16(2):87-110. PubMed ID: 7577773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabotropic glutamate receptor 2 and 3 gene expression in the human prefrontal cortex and mesencephalon in schizophrenia.
    Ghose S; Crook JM; Bartus CL; Sherman TG; Herman MM; Hyde TM; Kleinman JE; Akil M
    Int J Neurosci; 2008 Nov; 118(11):1609-27. PubMed ID: 18853337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurotransmitters and CNS disease. Schizophrenia.
    Snyder SH
    Lancet; 1982 Oct; 2(8305):970-4. PubMed ID: 6127468
    [No Abstract]   [Full Text] [Related]  

  • 36. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia.
    Demjaha A; Murray RM; McGuire PK; Kapur S; Howes OD
    Am J Psychiatry; 2012 Nov; 169(11):1203-10. PubMed ID: 23034655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. D1 and D2 and D3.
    Healy D
    Br J Psychiatry; 1991 Sep; 159():319-24. PubMed ID: 1683592
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharmacological differentiation of classical and novel antipsychotics.
    Arnt J
    Int Clin Psychopharmacol; 1998 Mar; 13 Suppl 3():S7-14. PubMed ID: 9690964
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psychopharmacological implications of dopamine and dopamine antagonists: a critical evaluation of current evidence.
    Hornykiewicz O
    Neuroscience; 1978; 3(9):773-83. PubMed ID: 30919
    [No Abstract]   [Full Text] [Related]  

  • 40. Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors.
    Carvalho RC; Fukushiro DF; Helfer DC; Callegaro-Filho D; Trombin TF; Zanlorenci LH; Sanday L; Silva RH; Frussa-Filho R
    Addict Biol; 2009 Jul; 14(3):283-93. PubMed ID: 19298320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.